ロード中...
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements
JAK2 fusion genes are rare but recurrent abnormalities associated with diverse, clinically heterogeneous hematologic malignancies. Here we assess the JAK1/2 inhibitor ruxolitinib as therapy for patients with JAK2-rearrangement associated myeloproliferative neoplasms (MPN). Ruxolitinib-treated Ba/F3...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Ferrata Storti Foundation
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3659945/ https://ncbi.nlm.nih.gov/pubmed/22875628 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.067959 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|